CytRx Wins Recommendation from DSMC to Complete Phase 2b Trial with Tamibarotene as First-Line Treatment for NSC Lung Cancer
Posted on January 31, 2013 at 08:34 AM EST
CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research and development company specializing in oncology, announced that the Data Safety Monitoring Committee overseeing the Company's global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) has recommended conducting the clinical trial